AChEIs Named — MRCPsych Paper B MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Donepezil, galantamine and rivastigmine
Explanation lettering: D = shown as C · E = shown as D · C = shown as E
The correct answer is B. Donepezil, galantamine and rivastigmine are acetylcholinesterase inhibitors recommended by NICE as monotherapy options for mild to moderate Alzheimer's disease. Memantine, included in options A, C and D, is an NMDA receptor antagonist rather than an acetylcholinesterase inhibitor. NICE recommends memantine monotherapy for severe Alzheimer's disease, or for moderate disease when acetylcholinesterase inhibitors are contraindicated or not tolerated; it may also be added to an existing acetylcholinesterase inhibitor in moderate or severe disease. Sertraline in option E is an SSRI used principally to treat depressive and anxiety disorders and is not a cognitive enhancer for Alzheimer's disease.
Reference: National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers (NG97), recommendation 1.5.2. 2018, amended 2025. https://www.nice.org.uk/guidance/ng97/chapter/Recommendations